The number of adults living with diabetes has surpassed 800 million, and the World Health Organization has called the escalating prevalence of Type 2 diabetes an epidemic.

Screening and clinical trials are further advancing research to develop therapies that delay or prevent the progression to clinical disease in people at risk of developing Type 1 diabetes.

Drucker and his team study the molecular biology and physiology of the GLP-1 and GLP-2 molecules that regulate glucose metabolism, insulin secretion and energy balance.

Daniel Drucker, MD, a pioneering scientist whose research contributed to the development of the blockbuster GLP-1 medicines used to treat diabetes and obesity, was listed by TIME magazine as one of the 100 Most Influential People of 2024.

The report supports previous clinical trials that found the GLP-1 receptor agonist drug semaglutide reduced kidney disease progression in patients with Type 2 diabetes.

Children with Type 1 diabetes are at increased risk for neurocognitive complications. Vanderbilt University Medical Center has been selected as one of 11 clinical centers in the United States to evaluate children newly diagnosed with Type 1 diabetes for neurocognitive outcomes.

With a $3 million research grant, Henrique Serezani will investigate how altered metabolism in diabetes affects inflammation and sepsis.